<DOC>
	<DOCNO>NCT01740596</DOCNO>
	<brief_summary>Sunshine Heart sponsor prospective , multi-center , randomized trial ass safety efficacy C-Pulse® System ( `` C-Pulse '' ) . The purpose study determine whether use C-Pulse treatment patient moderate severe heart failure ( HF ) demonstrate safety efficacy , C-Pulse System merit Food Drug Administration ( FDA ) approval market device United States .</brief_summary>
	<brief_title>C-Pulse® System : A Heart Assist Device Clinical Study</brief_title>
	<detailed_description>The C-Pulse® System indicate use patient moderate severe heart failure optimal heart failure drug device therapy . The C-Pulse® System intend relieve symptom heart failure , improve quality life cardiac function , reduce need heart failure hospitalization . It intend use hospital home . It intend replacement heart function ; life sustain life-supporting therapy . It preclude use heart failure therapy , valve surgery , heart transplantation LVAD . The Sunshine Heart C-Pulse System implantable , non-blood contacting , non-obligatory , heart assist device . The system provide cardiac assistance extra-aortic balloon Cuff ECG sense lead connect mean Percutaneous Interface Lead ( PIL ) external pneumatic Driver . The PIL hold secure externally , exit site , simple adhesive clip ( C-Patch similar ) immobilization external part PIL . The Driver adjust use dedicate notebook computer ( Programmer ) specialize software . The non-blood contacting feature C-Pulse® System also allow device intermittently turn tolerate . This allow patient freedom personal hygiene .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Left ventricular ejection fraction ( LVEF ) ≤ 35 % ( transthoracic ECHO within 90 day prior randomization ) 2 . ACC/AHA Stage C NYHA III ambulatory Class IV 3 . Age ≥ 18 year 4 . Must cardiac resynchronization therapy ( CRT ) clinically indicate , implant ≥90 day prior randomization . 5 . Must implant cardiodefibrillator ( ICD ) clinically indicate , implant least 30 day prior randomization . Note : If subject clinically indicated ICD refuse ICD , he/she may enrol . Please document refusal ICD medical record eCRFs . 6 . Patient must stable , uptitrated medical therapy recommend accord current guideline ( Circulation . 2009 ; 119 ( 12 ) : 19772016 ) minimally include : ACEinhibitor ( ACEI ) stable dos 1 month prior enrollment , tolerate , AND beta blocker ( carvedilol , sustain release metoprolol succinate , bisoprolol ) 3 month prior enrollment , tolerate , stable uptitrated dose 1 month prior enrollment . This also include Angiotensin II Receptor Blocker ( ARB ) stable dos 1 month prior enrollment , tolerate , ACEI tolerate . Stable define 100 % increase 50 % decrease dose . If patient intolerant ACEI , ARB , beta blocker , document evidence must available . In intolerant ACEI ARB , combination therapy hydralazine oral nitrate consider . Therapeutic equivalence ACEI substitution allow within enrollment stability timeline . Aldosterone inhibitor therapy add . Eplerenone require dosage stability 1 month prior enrollment . Diuretics may use necessary keep patient euvolemic . 7 . Functional limitation due heart failure define 6 Minute Walk test ≥ 175 ≤ 375 meter , measure within 30 day prior randomization 8 . At least one hospitalization decompensated heart failure define , heart failure medication , within 12 month prior randomization BNP level &gt; 300 NTproBNP &gt; 1500 Heart failure relate hospitalization define follow : sign symptom worsen heart failure ; treatment intravenous heart failure therapy ( include limit diuretic inotropic therapy ) minimum one date change hospital 9 . Patient understands nature procedure ongoing device therapy , willing comply associate followup evaluation , provide write informed consent prior procedure . 1 . Any evidence , assess within 90 day prior enrollment , either : 1 . Ascending aortic calcification posterioranterior lateral chest xray 2 . Calcific ascend aortic disease detect noncontrast CT scan 3 . Ascending aortocoronary artery bypass graft , history aortic dissection , Marfans disease connective tissue disorder repair aortic coarctation OR 4 . Has ascend aortic composite graft root replacement 2 . Aorta conform specify dimensional constraint define CT scan , specifically mid ascend aortic outside diameter le 28 mm great 42 mm 3 . Inotrope dependence inability wean inotropic therapy 4 . ACC/AHA Stage D heart failure nonambulatory NYHA Class IV subject 5 . Hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy , pericardial disease , amyloidosis , active myocarditis , diastolic heart failure technically challenging congenital heart disease 6 . Reversible cause heart failure may remedied conventional surgery intervention 7 . Moderate severe aortic insufficiency ( ≥ 2+ ) 8 . ST elevation myocardial infarction ( STEMI ) within 30 day prior randomization 9 . Cardiac surgery within 90 day prior randomization 10 . Prior cardiac transplantation , leave ventricular reduction surgery , passive restraint device surgically implant leave ventricular assist device 11 . Anticipated concomitant cardiac surgical procedure 12 . Serum creatinine ≥ 2.5mg/dL form dialysis within 30 day prior randomization 13 . Evidence intrinsic hepatic disease define biopsy proven liver cirrhosis ; liver enzyme value ( AST , ALT total bilirubin ) &gt; 3 time upper limit normal within 30 day prior randomization 14 . Patient severe intrinsic pulmonary disease judgment investigator 15 . Body Mass Index ( BMI ) &lt; 18 &gt; 45 kg/m2 16 . Suspected active systemic infection 1 . Within 14 day prior randomization 2 . Evidenced positive culture , antibiotic empiric treatment elevate WBC &gt; 12K temperature &gt; 38o C 17 . Stroke transient ischemic attack ( TIA ) within 90 day prior randomization ; &gt; 80 % carotid stenosis determine carotid Doppler ultrasound within 90 day prior randomization 18 . Positive serum pregnancy test , woman childbearing potential 19 . Patient condition , heart failure , would limit survival less 2 year 20 . Patient currently enrol participate last 30 day another therapeutic interventional clinical study 21 . Patient demonstrate compliance issue opinion investigator could interfere ability manage therapy ( i.e . uncontrolled diabetes , mental health issue , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>NYHA III</keyword>
	<keyword>NYHA IV</keyword>
	<keyword>ACC Stage C</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>C-Pulse</keyword>
	<keyword>Counterpulsation</keyword>
	<keyword>Heart Assist</keyword>
	<keyword>Sunshine Heart</keyword>
	<keyword>Left Heart Failure</keyword>
</DOC>